Max India Limited [MAXIND] vs Dr. Agarwal's Eye [DRAGARWQ] Detailed Comparison

Max India Limited
NSE
Loading...

Dr. Agarwal's Eye
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Max India Limited wins in 7 metrics, Dr. Agarwal's Eye wins in 11 metrics, with 0 ties. Dr. Agarwal's Eye appears stronger overall.
View Metrics Details
Vital Metrics Comparison
Metric | Max India Limited | Dr. Agarwal's Eye | Better |
---|---|---|---|
P/E Ratio (TTM) | -7.15 | 37.47 | Max India Limited |
Price-to-Book Ratio | 2.67 | 9.80 | Max India Limited |
Debt-to-Equity Ratio | 28.52 | 158.94 | Max India Limited |
PEG Ratio | -0.05 | 449.59 | Max India Limited |
EV/EBITDA | -11.04 | 20.13 | Max India Limited |
Profit Margin (TTM) | -85.52% | 13.76% | Dr. Agarwal's Eye |
Operating Margin (TTM) | -85.64% | 21.43% | Dr. Agarwal's Eye |
EBITDA Margin (TTM) | N/A | 21.43% | N/A |
Return on Equity | -32.99% | 29.80% | Dr. Agarwal's Eye |
Return on Assets (TTM) | -9.13% | 8.91% | Dr. Agarwal's Eye |
Free Cash Flow (TTM) | $-1.63B | $-83.80M | Dr. Agarwal's Eye |
Dividend Yield | N/A | 0.11% | N/A |
1-Year Return | -31.33% | 11.35% | Dr. Agarwal's Eye |
Price-to-Sales Ratio (TTM) | 7.04 | 5.21 | Dr. Agarwal's Eye |
Enterprise Value | $8.54B | $23.85B | Dr. Agarwal's Eye |
EV/Revenue Ratio | 5.20 | 6.01 | Max India Limited |
Gross Profit Margin (TTM) | 66.74% | 58.37% | Max India Limited |
Revenue per Share (TTM) | $38 | $845 | Dr. Agarwal's Eye |
Earnings per Share (Diluted) | $-30.72 | $116.64 | Dr. Agarwal's Eye |
Beta (Stock Volatility) | 0.22 | -0.34 | Dr. Agarwal's Eye |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Max India Limited vs Dr. Agarwal's Eye Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
Stock | 1D | 1W | 1M | 3M | 6M | YTD |
---|---|---|---|---|---|---|
Max India Limited | 1.67% | 9.98% | 17.27% | 6.86% | -10.74% | -19.66% |
Dr. Agarwal's Eye | 1.41% | -0.87% | 2.08% | 4.30% | -11.95% | -31.98% |
Long-term Returns
Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
---|---|---|---|---|---|---|
Max India Limited | -31.33% | 201.99% | 187.88% | 187.88% | 187.88% | 187.88% |
Dr. Agarwal's Eye | 11.35% | 561.32% | 1,800.83% | 2,763.70% | 5,203.40% | 14,891.42% |
Performance & Financial Health Analysis: Max India Limited vs Dr. Agarwal's Eye
Metric | MAXIND | DRAGARWQ |
---|---|---|
Market Information | ||
Market Cap | ₹11.57B | ₹20.68B |
Market Cap Category | Small cap | Small cap |
10 Day Avg. Volume | 199,719 | 1,146 |
90 Day Avg. Volume | 97,862 | 1,400 |
Last Close | ₹223.11 | ₹4,403.45 |
52 Week Range | ₹169.00 - ₹327.90 | ₹3,500.00 - ₹7,300.00 |
% from 52W High | -31.96% | -39.68% |
All-Time High | ₹338.00 (Jul 08, 2024) | ₹7,300.00 (Dec 30, 2024) |
% from All-Time High | -33.99% | -39.68% |
Growth Metrics | ||
Quarterly Revenue Growth | -0.01% | 0.21% |
Quarterly Earnings Growth | N/A | 0.25% |
Financial Health | ||
Profit Margin (TTM) | -0.86% | 0.14% |
Operating Margin (TTM) | -0.86% | 0.21% |
Return on Equity (TTM) | -0.33% | 0.30% |
Debt to Equity (MRQ) | 28.52 | 158.94 |
Cash & Liquidity | ||
Book Value per Share (MRQ) | ₹83.04 | ₹445.96 |
Cash per Share (MRQ) | ₹43.46 | ₹52.76 |
Operating Cash Flow (TTM) | ₹-1,276,000,000 | ₹944.80M |
Levered Free Cash Flow (TTM) | ₹-1,758,942,976 | ₹-279,437,504 |
Dividends | ||
Last 12-Month Dividend Yield | N/A | 0.11% |
Last 12-Month Dividend | N/A | ₹5.00 |
Valuation & Enterprise Metrics Analysis: Max India Limited vs Dr. Agarwal's Eye
Metric | MAXIND | DRAGARWQ |
---|---|---|
Price Ratios | ||
P/E Ratio (TTM) | -7.15 | 37.47 |
Forward P/E | N/A | 449.59 |
PEG Ratio | -0.05 | 449.59 |
Price to Sales (TTM) | 7.04 | 5.21 |
Price to Book (MRQ) | 2.67 | 9.80 |
Market Capitalization | ||
Market Capitalization | ₹11.57B | ₹20.68B |
Enterprise Value | ₹8.54B | ₹23.85B |
Enterprise Value Metrics | ||
Enterprise to Revenue | 5.20 | 6.01 |
Enterprise to EBITDA | -11.04 | 20.13 |
Risk & Other Metrics | ||
Beta | 0.22 | -0.34 |
Book Value per Share (MRQ) | ₹83.04 | ₹445.96 |
Financial Statements Comparison: Max India Limited vs Dr. Agarwal's Eye
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
Metric (MRQ) | MAXIND | DRAGARWQ |
---|---|---|
Revenue/Sales | ₹415.20M | ₹998.30M |
Cost of Goods Sold | ₹138.10M | ₹415.60M |
Gross Profit | ₹277.10M | ₹582.70M |
Research & Development | N/A | N/A |
Operating Income (EBIT) | ₹-450.50M | ₹213.90M |
EBITDA | ₹-372.20M | ₹316.90M |
Pre-Tax Income | ₹-453.00M | ₹186.00M |
Income Tax | ₹7.90M | ₹26.10M |
Net Income (Profit) | ₹-460.90M | ₹159.90M |
Balance Sheet & Liquidity Metrics (MRQ)
Metric (MRQ) | MAXIND | DRAGARWQ |
---|---|---|
Cash & Equivalents | ₹227.00M | ₹111.60M |
Total Current Assets | ₹2.61B | ₹559.40M |
Total Current Liabilities | ₹1.65B | ₹869.80M |
Long-Term Debt | ₹958.90M | ₹3.06B |
Total Shareholders Equity | ₹3.59B | ₹2.10B |
Retained Earnings | N/A | N/A |
Property, Plant & Equipment | ₹1.53B | ₹3.65B |
Cash Flow Statement Comparison (MRQ)
Metric (MRQ) | MAXIND | DRAGARWQ |
---|---|---|
Operating Cash Flow | N/A | N/A |
Capital Expenditures | N/A | N/A |
Free Cash Flow | N/A | N/A |
Debt Repayment | N/A | N/A |
Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
Metric | MAXIND | DRAGARWQ |
---|---|---|
Shares Short | N/A | N/A |
Short Ratio | N/A | N/A |
Short % of Float | N/A | N/A |
Average Daily Volume (10 Day) | 199,719 | 1,146 |
Average Daily Volume (90 Day) | 97,862 | 1,400 |
Shares Outstanding | 46.15M | 4.70M |
Float Shares | 23.53M | 1.11M |
% Held by Insiders | 0.51% | 0.78% |
% Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Max India Limited vs Dr. Agarwal's Eye
Metric | MAXIND | DRAGARWQ |
---|---|---|
Last 12-Month Dividend | N/A | ₹5.00 |
Last 12-Month Dividend Yield | N/A | 0.11% |
3-Year Avg Annual Dividend | N/A | ₹4.50 |
3-Year Avg Dividend Yield | N/A | 0.12% |
3-Year Total Dividends | N/A | ₹13.50 |
Ex-Dividend Date | N/A | Nov 08, 2024 |